GEN Exclusives

More »

GEN News Highlights

Back to Item »

Servier Inks Deal with Xoma with $35M Up Front to Develop IL-1 Antibody

Xoma 052 is expected to start in Phase III trials for Behcet’s uveitis this year.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Genetic Testing for Children and Adolescents

Do you think parents should have predictive testing carried out on their children and adolescents?

More »